Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
China's FDA is proposing new policies to hasten clinical trial approval and lift restrictions placed on trial sites.
PPD has put its medical affairs research operations team under Evidera, the evidence-based solutions subsidiary PPD bought last year.
China's FDA and Supreme Court, in a seemingly synchronized move, are proposing new actions against forging clinical trial data, and criminal charges are…
Texas-based Moleculin Biotech penned a deal with Theradex Systems to help it run early-stage trials for its candidate annamycin in acute myeloid leukemia.
A bipartisan bill that plans to allow a tax credit for expenses of contracted research—often done by CROs—has been introduced in the House of Representatives.
The European Medicines Agency wants to suspend around 300 marketed generic meds and applications due to its concerns.
Charles River Laboratories has agreed to pay the U.S. government $1.8 million to settle allegations that it overbilled the NIH for contract services it didn’t…
The U.S. FDA selects Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials.
A recent study by German researchers found that postmarketing trials funded by the industry are not effective in identifying safety issues.
Parexel has launched an expanded Managed Access Programs service to streamline patients’ access to compassionate use of investigational medical products.